Compare Amphastar Pharmaceuticals Inc (AMPH) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Booz Allen Hamilton Holding Corporation trades at $64.08 (market cap $7.53B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 9.1× Amphastar Pharmaceuticals Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.76% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BAH | |
|---|---|---|
Market Cap | $826.08M | $7.53B |
Sector | Health | Industrials |
52-Week High | $30.81 | $115.95 |
52-Week Low | $16.87 | $59.71 |
Enterprise Value | $1.22B | $10.92B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Booz Allen Hamilton (BAH) trades at $62.76, down 0.63% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.1 and robust profitability, including an 80.17% ROE. Recent earnings have mostly beaten estimates, and the company announced a partnership with OpenAI to advance AI in national security. Cash flow from operations improved to $1.01B in 2025, though net cash flow turned negative in 2026 projections.
BAH presents a compelling value opportunity with solid earnings growth and a consensus price target of $80.80, implying significant upside. Risks include persistent civil segment weakness noted in guidance and rising debt-to-asset ratios. Investor sentiment is mixed, with nearly half of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
